Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; none of the 42 sources its claims cite is checked for support yet.

Delays in breast cancer presentation, diagnosis, and treatment in young women

Open access

Abstract

Background: Breast cancer (BC) in young patients is often identified at later stages, which can result in poor prognosis. It is important to investigate the factors influencing care delays and how delays affect outcomes. Methods: This study included women aged ≤40 years at diagnosis of stage 0–IV BC in the Young Women’s Breast Cancer Study enrolled between 2006 and 2016. Associations between patient and tumor factors and presentation delay (first symptom to provider visit, ≥90 days), diagnostic delay (presentation to diagnosis, ≥90 days), and treatment delay (diagnosis to treatment, ≥60 days) were estimated via logistic regression. Multivariable logistic models for delays were constructed via backward selection ( p ≤ .05 retained). Multivariable Cox proportional hazards models tested the association between delays and disease‐free survival (DFS) and overall survival (OS). Analyses were stratified by tumor subtype and stage. Results: Among 1071 women, there were 153 presentation, 120 diagnostic, and 228 treatment delays. In multivariable models, lower annual income was associated with higher odds of presentation delay, whereas pregnancy at diagnosis, family history of BC, and triple‐negative (TN) subtype were associated with lower odds. In HER2‐positive luminal B tumors, presentation delays were associated with later stage ( p < .001). Odds of diagnostic delay were higher for younger patients and lower for those with TN tumors. Patients with more aggressive tumor subtypes were less likely to have treatment delays. Delays were not associated with DFS or OS. Conclusions: In this cohort of young patients with BC, demographic and tumor factors were associated with delays in care. It is reassuring that delays did not influence disease outcomes.

Overview

CoChat Summary

TL;DR

In a prospective cohort of 1071 women aged ≤40 years with stage 0–IV breast cancer, 14% had presentation delay, 11% had diagnostic delay, and 22% had treatment delay. Delays were not independently associated with worse disease-free or overall survival, but presentation delay was linked to later stage in HER2-positive luminal B tumors.

Key findings

  • Median times were 14 days (IQR, 2–45) from first symptom to presentation, 14 days (IQR, 7–30) from presentation to diagnosis, and 41 days (IQR, 25–57) from diagnosis to treatment. Presentation delay (≥90 days) occurred in 153 patients (14%), diagnostic delay (≥90 days) in 120 (11%), and treatment delay (≥60 days) in 228 stage 0–III patients (22%).
  • In multivariable models, presentation delay was associated with income <$50,000 (OR, 1.98; 95% CI, 1.22–3.13) and inversely with pregnancy at diagnosis (OR, 0.17; 95% CI, 0.01–0.80), first-degree family history of breast cancer (OR, 0.40; 95% CI, 0.17–0.80), and TNBC versus luminal A (OR, 0.29; 95% CI, 0.13–0.60). Diagnostic delay was inversely associated with age (OR per year, 0.94; 95% CI, 0.90–0.99) and TNBC versus luminal A (OR, 0.35; 95% CI, 0.16–0.70). Treatment delay was inversely associated with TNBC versus luminal A (OR, 0.26; 95% CI, 0.14–0.45) and stage III versus stage I (OR, 0.36; 95% CI, 0.19–0.63).
  • Presentation delay was associated with later stage at diagnosis among HER2-positive luminal B tumors (OR for stage III/IV vs. stage I/II, 3.19; 95% CI, 1.48–6.87; p < .001). Presentation and diagnostic delays were not significantly associated with DFS or OS; treatment delay was associated with longer DFS (unadjusted HR, 0.46; 95% CI, 0.30–0.71; fully adjusted HR, 0.51; 95% CI, 0.33–0.78) and longer OS in some models, but the OS association disappeared after adjustment for treatment and stage.

Methods

  • Prospective cohort: Young Women’s Breast Cancer Study, 13 academic and community sites in the United States and Canada, enrolling women aged ≤40 years at diagnosis of stage 0–IV breast cancer between 2006 and 2016; 1071 of 1297 patients were included, with baseline surveys usually completed within 6 months of diagnosis (average 4 months from diagnosis).
  • Exposures: patient-reported time from first symptom to provider visit (presentation delay ≥90 days), provider visit to diagnosis (diagnostic delay ≥90 days), and medical-record diagnosis to first treatment (surgery or chemotherapy, treatment delay ≥60 days). Univariable and multivariable logistic regression with backward selection (p ≤ .05 retained) assessed factors associated with delays; Cox proportional hazards models assessed DFS and OS, stratified by tumor subtype and stage, with mediation analysis.
  • Survival analyses: DFS among 928 stage I–III patients over median follow-up of 12.3 years (IQR, 10.5–15.0); OS among 984 stage I–IV patients with 157 deaths. Treatment-delay models used left truncation from first treatment and adjusted for age, subtype, surgery, chemotherapy, radiation, and stage.

Limitations

  • Stated in the paper: timing from symptom onset to presentation was patient-reported, with possible misclassification; the cohort was limited in racial, ethnic, and socioeconomic diversity, consisting mostly of White, insured patients with higher-than-average incomes; active research participants may have higher health-seeking behaviors than the general population.
  • Stated in the paper: small numbers within subgroups limited some analyses; lack of gene expression data may limit histologic subtype classification; results were driven by patients with luminal-like disease, leaving questions for HR-negative/HER2-positive and TNBC patients; quality-of-life outcomes were not measured.
  • Evident in the text: the observational design cannot establish causality; delay thresholds (≥90 or ≥60 days) are predefined cutoffs; residual confounding and limited subgroup power may affect the null survival findings.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1002/cncr.70594

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 26 Not checked · 73 Own results and interpretations

31 more claims

Create a free account to see all 99 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 42
  • Probably not a substantial claim. 25

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 7 · the rest aren’t loaded

2 more findings

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Cited by

Still being checked.

Metadata

Authors
Zhang, B. X., Sella, T., Zheng, Y., Kirkner, G. J., Ruddy, K. J., Rosenberg, S. M., Borges, V. F., Schapira, L., Come, S. E., Peppercorn, J. M., Collins, L., Partridge, A. H., & Brantley, K. D.
Affiliations
  • Brigham and Women's Hospital (US)
  • Harvard University (US)
  • Dana-Farber Cancer Institute (US)
  • Mayo Clinic (US)
  • Weill Cornell Medicine (US)
  • University of Colorado Cancer Center (US)
  • Stanford Medicine (US)
  • Beth Israel Deaconess Medical Center (US)
Corresponding author
Brantley, Kristen D.
Venue
Cancer
Publisher
Wiley
Published
2026-10-12
Volume
132
Issue
20
Pages
e70594-e70594
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W7221518840
Cited by
0
References
63
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
breast cancer, young women, delayed care, delayed presentation, delayed diagnosis, treatment delay, triple-negative breast cancer, tumor subtypes, family history of breast cancer, income, disease-free survival, overall survival
MeSH terms
Treatment Delay, Adult, Breast Neoplasms, Female, Humans, Neoplasm Staging, Prognosis, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Young Adult, Delayed Diagnosis, Time-to-Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.